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Abstract 
We report a case of eosinophilic pneumonia (EP) in an infant patient. Such cases are 
rare and the purpose of this study is to combine this case and the english literature 
available in order to expand our knowledge regarding the therapeutic strategies for 
this disease.Currently we can define a specific therapeutic guideline for patients with 
EP.It is important to expand our knowledge and experience regarding this 
ailment.More studies are needed to better understand this rare disease, to more 
precisely define diagnostic and therapeutic strategies and to find out and asses new 
treatment methods. 
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Abbreviations: 
 
EP: Eosinophilic Pneumonia 
 
AEP: Acute Eosinophilic Pneumonia 
 
CEP: Chronic Eosinophilic Pneumonia 
 
HES: Hypereosinophilic Syndrome 
 
GPA: Granulomatosis with polyangiitis 
 
WG: Wegener’s Granulomatosis 
 
 BAL: Bronchoalveolarlavage 
 
PEC:peripheral eosinophil count 
 
IgE: Immunoglobulin E 
 
CXR: Chest X-ray 
 
CT: Computed tomography 
 
RT: Radiation therapy 
 
Th2: T helper 2 
 
BALF: Bronchoalveolar lavage fluid 
 
pNTM: pulmonary non-tuberculous mycobacteriosis 
 
IL: Interleukin 
 
anti-IL: anti-Interleukin 
 
FEV1: forced expiratory volume in 1 second 
 
PGD2: Prostaglandin D2 
 
AQLQ: Asthma Quality of Life Questionnaire 
 
ACQ: Asthma Control Questionnaire 
 
T2: Type 2 
 
Th2: T helper cell type 2 
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Introduction 
Eosinophil 
The purpose of this article is to further 
explore the topic of eosinophilic 
pneumonia (EP), as well as discuss 
current and future treatment options 
through a detailed literature 
review.Eosinophils, sometimes called 
eosinophils or, less commonly, 
acidophils, are a variety of white blood 
cells and one of the immune system 
components responsible for combating 
multicellular parasites and certain 
infections in vertebrates.(Cincinnati, 
available 
https:www.cincinnatichildrens.org) 
The eosinophil is in other words an 
end-stage granulocyte which is 
developed in the bone marrow, where 
it also differentiates from myeloid 
precursor cells(Lambrecht et. al., 2015; 
Metcalf D et. al., 1987, 1986; 
Yamaguchi et. al., Y 1988) and is 
known to circulate through the 
peripheral bloodstream and tissues. 
The eosinophil is composed of many 
granules containing enzymes and 
proteins (Stephanie S et. al., 2016; 
Adkinson NF et. al., 2014). Following 
activation by an immune stimulus, 
eosinophils degranulate to release an 
array of cytotoxic granule cationic 
proteins that are capable of inducing 
tissue damage and dysfunction.(Gleich 
GJ et. al., 1986)While normally 
appearing in smaller numbers in 
healthy people, eosinophils play a 
central role in inflammation and 
allergic process. (Waedlaw AJ et. al., 
2000; Scott KA et. al., 2006; Adkinson 
NF et. al., 2009)  They control 
mechanisms associated with allergy 
and asthma.The functional ambiguity 
of the Eosinophils belies a rich history 
of experimentation and evolving 
hypotheses that have slowly defined 
the importance of eosinophils as 
components of disease processes and 
the maintenance of homeostasis. (Lee 
J.J. et. al., 2012; Furuta GT. et. al., 
2014) An understanding of the 
historical context surrounding 
eosinophil biology is relevant as these 
changing perspectives developed from 
an underlying need to explain clinical 
observations and improve patient 
disease management. While they are 
released into the bloodstream as 
neutrophils are, eosinophils reside in 
tissue. (Rosenberg HF et. al., 2007) 
They are found in the medulla and the 
junction between the cortex and 
medulla of the thymus, and, in the 
lower gastro-intestinal tract, ovaryes, 
uterus, spleen, and lymph nodes, but 
not in the lungs, skin, esophagus, or 
some other internal organs[vague] 
under normal conditions. The presence 
of eosinophils in these latter organs is 
associated with disease. For instance, 
patients with eosinophilic asthma have 
high levels of eosinophils that lead to 
inflammation and tissue damage, 
making it more difficult for patients to 
breathe.(Lambrecht BN et. al., 2015; 
Sanderson et. al., 1992)  Some recent 
studies have suggested that peripheral 
blood eosinophil levels or the 
peripheral levels of unique eosinophil-
specific markers correlate with disease 
severity (Furuta GT. et. al., 2014; 
Robinson D. S. et. al., 1995) the 
limited power of these studies and the 
publication of reports with conflicting 
conclusions (Stelmach P. et. al., 2004) 
have limited the usefulness of these 
systemic evaluations. Instead, the goals 
of assessment in these diseases have 
been site-specific sampling. 
 
Pneumonia (Generally) 
Pneumonia is an inflammatory 
condition of the lung affecting 
primarily the small air sacs known as 
alveoli. (Hui E. et. al., 2014; McLuckie 
et. al., 2009) Severity is variable. 
(Leach et. al., 2009) Pneumonia affects 
approximately 450 million people 
globally (7% of the population) and 
results in about 4 million deaths per 
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year. (Ashy B. et. al., 2007; Ruuskanen 
O. et. al., 2011). 
 
Eosinophilic Pneumonia (EP) 
Eosinophilic pneumonias (EPs) belong 
to the large group of interstitial lung 
diseases. (Lodha R. et. al., 2013; 
Giovannini L. et. al., 2016) They are 
characterized by a significant 
infiltration of the alveolar spaces and 
lung interstitium by eosinophils, with 
conservation of the lung structure. 
Eosinophilic pneumonia (EP), is also 
known as pulmonary infiltrates with 
eosinophilia (PIE syndrome), is a rare 
and heterogeneous syndrome that is 
classified according to inveteracy and 
etiology. This syndrome first described 
in 1989. (Nathan N. et. al., 2012; 
Bartal C. et. al., 2018) The currently 
used classification system of EP was 
described by Allen and Davis in 1994 
(Allen JN. et. al., 1989) EP is 
infectious. It spreads through sneezes 
or coughs, but it spreads slowly. 
Eosinophilic pneumonia is divided into 
different categories depending upon 
whether a cause can be determined or 
not. Known causes include certain 
medications or environmental triggers, 
parasiticinfections, and cancer. EP can 
also occur when the immune system 
attacks the lungs, a disease called 
eosinophilic granulomatosis with 
polyangiitis. When a cause cannot be 
found, the EP is labeled "idiopathic". 
Idiopathic EP can be divided into 
"acute eosinophilic pneumonia" (AEP) 
and "chronic eosinophilic pneumonia" 
(CEP) depending on the symptoms a 
person is experiencing. (Allen JN et. 
al., 1994) The following table 
represents the classification of the EPs. 
The various types of eosinophilic 
pneumonia have similar signs and 
symptoms. In particular acute 
eosinophilic pneumonia typically 
follows a rapid course. Chronic 
eosinophilic pneumonia usually 
follows slower course.The symptoms 
accumulate over several 
months.Individuals with CEP are often 
misdiagnosed with asthma before CEP 
is finally recognized. When 
eosinophilic pneumonia is related to an 
illness such as cancer or parasitic 
infection, treatment of the underlying 
cause is effective in resolving the lung 
disease. When due to AEP or CEP, 
however, treatment withcorticosteroids 
results in a rapid, dramatic resolution 
of symptoms over the course of one or 
two days. Either 
intravenousmethylprednisolone or oral 
prednisone are most commonly used. 
In AEP, treatment is usually continued 
for a month after symptoms disappear 
and the x-ray returns to normal. In 
CEP, treatment is usually continued for 
three months after symptoms disappear 
and the x-ray returns to normal.In 
summary, eosinophils in the 
respiratory system can produce a wide 
array of symptoms, leading to many 
common as well as some more rare 
disease processes. While eosinophils 
can affect many different organ 
systems, eosinophil pathology in the 
respiratory system is a commonly 
encountered issue affecting both 
pediatric and adult populations. The 
involvement of eosinophils in 
pulmonary disease processes can affect 
the method of diagnosis and the 
selection of treatment modalities. By 
analyzing the complex interaction 
between the eosinophil and its 
environment, which includes signaling 
molecules and tissues, different 
therapies have been discovered and 
created in order to target disease 
processes at a cellular level. The topic 
of innovative treatments such as 
mepolizumab, benralizumab 
lebrikizumab dupilumab reslizumab 
and omalizumab will be explored in 
the following sections. 
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Table 1: Classification of eosinophilic pulmonary diseases
 
A) Idiopathic eosinophilic lung diseases 
 
B) Secondary eosinophilic lung diseases 
 
Löffler Syndrome (Simple Pulmonary 
Eosinophilia) 
Acute Eosinophilic Pneumonia (AEP) 
Chronic Eosinophilic Pneumonia (CEP) 
Hypereosinophilic Syndrome (HES) 
 
1. Medication triggered 
Aminosalicylic acid Bicalutamide 
Non-Steroidal Anti-Inflammatory Imipramine 
Bleomycin Interleukin-2 and -3 
Captopril Mecylamine 
Cocaine Methylphenidate 
Sodium Chromogluconate Minocycline 
Ethambutol Phenytoin 
Salts of gold Trazodone 
Heroin Trimipramine 
 
 2. Parasitic causes 
Ascariasis 
Paragonimiasis 
Strongyloidiasis 
Tropical eosinophilia 
Ancylostomiasis 
Schistosomiasis 
 
 3. Fungal etiology 
Allergic Bronchopulmonary Aspergillosis 
Coccidioidomycosis 
Trichosporonosis 
Invasive aspergillosis 
Other fungi 
 
 4. Bacterial etiology 
 
 5. Viral etiology 
 
 6. Connective tissue diseases and vasculitis  
Granulomatosis with polyangiitis (GPA) or  
Wegener's Granulomatosis (WG) 
Eosinophilic Granulomatosis with Polyangiitis 
(Churg-Strauss Syndrome) 
Rheumatoid arthritis 
Polyarteritis nodular 
 
 7. Inhalation of toxic gases 
 
 8. Other (unclassified) eosinophilic lung 
diseases 
Eosinophilic Gastroenteritis 
Vascularimmunoblastic 
Lymphadenopathy 
Reptile Bite Hysteocytosis - X 
Inflammatory Bowel Disease Malignant 
Diseases 
Bone marrow transplantation of Idiopathic 
Pulmonary 
Fibrosis 
Asthma Eosinophilic Bronchitis 
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Case Presentation 
4, 5-Month-Old female died during 
transport to the hospital and then the 
following results raised from the 
autopsy and autopsy histopathology. 
 
Materials and Methods 
Macroscopic findings: I received in a 
plastic container with formalin: 
 
      A. Brain tissue of 10 x 9 x 2 cm 
and weighing 89.7 g. 
      B. En bloc intestines with a total 
weight of 477.8 g, consisting of: 
          1. Tongue, trachea and aorta. 
          2. Heart of dimensions 5,5 x 4 x 
2,5 cm and weighing 34,6 g. 
          3. Right lung with larger 
dimension more than 9 cm long and 
left lung with larger dimension  
          of 8.5 cm. 
          4. Stomach, liver and spleen. 
          5. Right kidney with larger 
dimension of 5 cm and a left kidney 
with larger dimension of   
          4.8cm. 
 
Results 
Microscopic examination: 
A. Brain tissue with localized 
destruction of the brain matter, edema, 
cells with eosinophilic cytoplasm and 
deep-chromatic nuclei, with the 
presence of inflammatory summations 
and varying degrees of congested 
vessels with localized overlapping 
wall. 
B.  
1. Tongue and trachea in places with 
mild inflammatory infiltrates, while six 
lymph nodes are recognized. Aorta in 
which within the lumen there are 
inflammatory effusion, fibrin, 
phagocytes and hemosiderin granules. 
2. Myocardium with autolysis sites, 
localized medial edema, focal 
interstitial fibrosis mainly perivascular, 
areas in which the myocardial fibers 
exhibit cortical morphology and local 
disorder in terms of their layout. Also, 
inflammatory cells, mainly eosinophils 
and lymphocytes, phagocytes, 
hemosiderin granules, are recognized, 
while inflammatory effusion with 
fibrin and hemosiderin granules, as 
well as thickened vessels, are locally 
detected intra-cardiac. 
3. Pulmonary parenchyma in places 
with edema, with the presence of 
relatively sparse eosinophilic material 
in alveoli and bronchioles, areas with 
fibrous connective tissue in dense 
layout, whereas foci with condensing 
of the alveoli are found, areas with 
bronchial / bronchiolar / alveolar 
destruction are found to varying 
degrees in the fibrin reticulum bronchi, 
inflammatory effusion, relatively thick 
eosinophilic vitreous membranes, and 
concretion of cells and locally relative 
increase of mucus secreting cells. 
Inflammatory infiltrates, mainly 
eosinophilic cells and lymphocytes, 
abundant phagocytes, hemosiderin 
granules are also recognized, with the 
presence of multinucleated giant cells, 
impacted corpuscles, lymph nodes, and 
arterioles with overlapping wall. 
4. Stomach in places with mild 
inflammatory infiltrates. 
Liver with localized relatively 
distended sinusoids, autolysis sites and 
necrosis sites, mild inflammatory 
summations, phagocytes and 
hemosiderin granules. Spleen with 
locally distended pulp crossbeams, 
areas with fibrosis, multiple 
phagocytes and hemosiderin granules. 
5. Renal parenchyma in which there 
are autolysis sites, inflammatory cells, 
phagocytes, hemosiderin granules and 
arterioles are sparsely scattered with 
overlapping wall are found to some 
extent congested. 
 
Discussion 
The types of Eosinophilic Pneumonia 
(EP) have been previously mentioned. 
The characteristics of AEP and CEP 
are going to be mentioned below.Acute 
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eosinophilic pneumonia (AEP) is 
notable for diffuse pulmonary 
infiltrates and elevated pulmonary 
eosinophils in the presence of high-
grade fevers and may rapidly progress 
to acute respiratory failure. In addition 
to fever, nonproductive cough, 
shortness of breath, fatigue, myalgias, 
night sweats, and pleuritic chest pain 
may be present.  (Pigakis K. et. al., 
2008) Clinical exam findings include 
tachypnea, tachycardia, and crackles or 
rhonchi on lung auscultation. 
Radiographic findings on chest X-ray 
(CXR) include pulmonary edema, 
Kerley B lines, pleural effusions, and 
diffuse pulmonary infiltrates, which 
are more central and not 
characteristically seen in peripheral 
lung fields. Characteristic findings on 
computed tomography (CT) of the 
chest include diffuse interstitial and 
patchy alveolar infiltrates leading to a 
ground glass appearance. (Michael E. 
et. al., 2007) AEP affects males twice 
as often as females and can occur at 
any age, though the average age of 
onset is about 30 years. (Daimon T. et. 
al., 2008)  Patients do not typically 
have a previous history of asthma. The 
etiology of the disease is unknown, but 
it is thought to be associated with 
environmental exposures. 
Bronchoalveolar lavage (BAL) is 
helpful for diagnosis, and identification 
of a concentration of greater than 25 % 
eosinophils is characteristic of the 
disorder. Interestingly, eosinophils are 
not elevated in the bloodstream on 
presentation of AEP. AEP is a 
diagnosis of exclusion, and other 
causes of acute respiratory failure such 
as infection or drugs must be ruled out. 
While a portion of affected patients 
may spontaneously recover, treatment 
with corticosteroids and respiratory 
support typically leads to 
improvement, usually without 
recurrence of disease. Abnormalities 
on imaging studies and pulmonary 
function tests usually return to normal 
once the disease is resolved. (Jang 
Won Sohn et. al., 2013; Philit et. al., 
2002; Rose et. al., 2013) 
Acute   eosinophilic   pneumonia   
should   be included in the differential 
diagnosis of pneumonia, especially in 
patients who have recently started 
smoking. A recent change in smoking 
habits is associated with acute 
eosinophilic pneumonia, as   are   other   
toxins. (Janz DR. et. al., 2009; D 
Caroline L H Brackel et. al., 2015; 
Seung Yong Park et. al., 2017) In 
particular, a significant number of 
drugs and toxins have been associated 
with eosinophilic pneumonia. Toxins 
suspected to cause eosinophilic 
pneumonia include cigarette smoke. 
(Lomon J et. al., 2006). The diagnosis 
is supported by a temporal relationship 
to a drug or toxin. The condition 
usually resolves with removal from the 
agent and recurs with rechallenge. 
Treatment involves discontinuation of 
the offending drug or toxin and 
treatment with corticosteroids in severe 
respiratory failure. (Takeuchi A. et. al., 
2016) The cause of AEP is unknown, 
but it has been suggested that it may 
represent an acute hypersensitivity 
reaction due to unidentified antigens. 
Smoking is thought to be a risk factor 
for the development of AEP. 
(Uchiyama H. et. al., 2008; Bok GH, 
et. al., 2008; Nakajima M. et. al., 2002) 
AEP can develop soon after initiation 
of smoking as well as rechallenge with 
smoking after a period of abstinence. 
(Min Kyung Chung et. al., 2014)
 
AEP 
has also been reported with 
secondhand smoke exposure. 
(Takeuchi A. et. al., 2016). Previous 
reports (Shiota Y. et. al., 2000; 
Shintani H. et. al., 2000; Watanabe K. 
et. al., 2002; Kitahara Y. et. al., 2003)
 
suggest that AEP is related not only to 
the new onset of smoking, but also to 
resumption of smoking or the increase 
in the quantity of cigarette smoking. 
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The mechanism by which cigarette 
smoke induces AEP is not fully 
known. Cigarette smoke has been 
shown to be a strong inflammatory 
stimulus that recruits macrophages and 
neutrophils to lung tissue, and further 
induces pro-inflammatory cytokines 
and chemokines, such as interleukin-6, 
tumor necrosis factor, and interleukin-
8. However, there is no concrete 
evidence that cigarette smoke itself 
directly induces eosinophilic 
inflammation in the lung. Recently, 
short-term cigarette smoke exposure 
has been shown to enhance pulmonary 
eosinophilic infiltration, as 
demonstrated by the marked increase 
in the levels of eotaxin in a mouse 
model of ovalbumin-induced allergic 
airway inflammation. (Nakajima M. et. 
al., 1997) Clinicians should maintain a 
high index of suspicion for AEP in any 
patient with a new smoking habit. This 
may be especially important in the 
military population, where the 
prevalence of tobacco use is higher 
than in the civilian sector. (Kuschner 
WG. et. al., 1996)
 
Clinical outcomes of 
corticosteroid treatment in patients 
with AEP are good, and most AEP 
patients improve rapidly. There are no 
controlled clinical trials to determine 
the duration of corticosteroid therapy 
for AEP.  Consequently, current 
practice derives from expert opinion 
(Jhun BW. et. al., 2014) without the 
assistance of clinical practice 
guidelines, which would help 
clinicians weigh the benefits relative to 
the potential harm of various durations 
of therapy.
 
(Heffner JE. et. al., 2015) 
Tapering of corticosteroids has been 
evaluated in a previous study. It 
demonstrated non-inferiority of 2-week 
compared with a 4-week corticosteroid 
treatment. (Demirjian L. et. al., 2006; 
Kramarow EA et. al., 2012) However, 
in that study, the tapering of 
corticosteroid was not adjusted to 
disease severity. All AEP patients 
received 2-week tapering. Only the 
mild cases underwent conservative 
treatment. We have no guidance to 
stratify disease severity of AEP, which 
may lead to overtreatment of mild 
cases. We have stratified AEP 
according to the presence of initial 
eosinophilia: AEP with initially normal 
PEC is considered a severe disease and 
AEP with initial eosinophilia is 
considered a milder disease. We 
developed a treatment protocol, with a 
rapid corticosteroid tapering strategy, 
in patients with initial eosinophilia. 
The most important finding in this 
study was that no treatment failure 
occurred in AEP patients with initial 
eosinophilia who underwent rapid 
corticosteroid tapering, strengthening 
the results, that an initially elevated 
PEC was associated with milder 
disease. (Kubo S. et. al., 2005; Jhun 
BW. et. al., 2015; Rhee CK. et. al., 
2013) These results suggest that 
shorter treatment courses of 
corticosteroid may be an acceptable 
strategy in managing AEP with initial 
eosinophilia. Unfortunately, what logic 
suggests would represent conservative 
and therefore safe therapy—giving 
corticosteroids long enough to ensure 
full recovery and prevent a relapse—
may actually cause harm if patients 
would have recovered sooner, but 
developed side effects from 
unnecessarily prolonged drug therapy. 
Of note, some patients with AEP 
recover spontaneously without 
corticosteroid treatment so it seems 
implausible that all patients who 
clinicians choose to treat will require a 
minimum of 2 weeks or more of drug 
therapy. In conclusion, the above 
mentioned data support as the best 
solution the individualization of 
therapy based on the severity of the 
initial disease and the response to 
corticosteroid therapy. Another study 
tried to evaluate the course of clinical 
stability in patients with acute 
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eosinophilic pneumonia (AEP) who 
did not receive corticosteroid 
treatment. Although the severity of 
AEP varies from mild dyspnea to life-
threatening respiratory failure (Jantz 
MA. et. al., 1999; Guyatt G. et. al., 
2006; Byung Woo et. al., 2015) AEP is 
characterized by a rapid response to 
corticosteroids.In addition, 
spontaneous recovery without any 
treatment has been reported, 
(Carrington CB et. al., 1969; Yunjie 
Ge. et. al., 2013; Hayakawa H. et. al., 
1994; Umeki S. et. al., 1992) even in 
patients with severe respiratory failure. 
(Pope-Harman A. et. al., 1996) In that 
study, AEP-associated symptoms and 
signs were spontaneously resolved 
within a median of 9 days. In addition, 
the majority of pulmonary infiltrates 
on chest radiographs also completely 
disappeared within 14 days after 
diagnosis. However, the peripheral 
eosinophil counts and the frequency of 
peripheral eosinophilia increased up to 
10 days and then decreased during the 
follow-up period. All patients in this 
study population experienced 
peripheral eosinophilia ([500/lL) 
during hospitalization. However, these 
findings might be limited to relatively 
mild cases of AEP. These data may 
assist physicians in determining the 
optimal timing for initiation of 
corticosteroids when clinical 
abnormalities are not resolved during a 
follow-up period without corticosteroid 
treatment.However, the clinical 
situations in which spontaneous 
resolution can be predicted at the time 
of diagnosis and which conservative 
treatments without corticosteroids are 
sufficient for patients with AEP remain 
unknown. Although spontaneous 
improvements have even been reported 
progression to life-threatening 
hypoxemia or death from AEP can 
occur. (Uchiyama H. et. al., 2008) 
Therefore, further studies of clinical 
characteristics or parameters that more 
precisely reflect the grade of the 
inflammatory process in AEP are 
required. 
First described by Charles B. 
Carrington in the New England Journal 
of Medicine in 1969, chronic 
eosinophilic pneumonia (CEP) is a rare 
disorder, with many reports of this 
illness being limited to case studies. 
(Kawayama T. et. al., 2002; Lim SY. 
et. al., 2012) Though the exact etiology 
is unknown, the disease is often 
associated with a high eosinophilic 
presence in lung tissue. (Philit F. et. 
al., 2002; Shorr AF et. al., 2004) In 
contrast with AEP, the majority of 
patients with CEP have a previous 
history of asthma. The presentation of 
CEP is variable, but tends to be a 
subacute or chronic course of mild 
symptoms. Pulmonary and 
hematologic eosinophilia are typical, 
and imaging studies reveal peripheral 
pulmonary infiltrates. Most patients are 
diagnosed in their third or fourth 
decade of life, though CEP may 
present in any age group. CEP has a 
predilection for women with a ratio of 
2:1 female to male diagnoses. The 
disease is more often seen in 
nonsmokers. Symptoms include cough, 
progressive dyspnea, chest pain, 
weight loss, night sweats, and fever. 
Patients with CEP, unlike patients with 
AEP, are likely to present with a 
slightly elevated temperature that is 
less than 38 °C. Diagnostic criteria for 
CEP includes pulmonary symptoms of 
at least 2-week duration, eosinophilia 
in the lung or blood- stream, peripheral 
pulmonary infiltrates on imaging 
studies, and exclusion of other 
common eosinophilic lung diseases. 
(Cottin V. et. al., 2005) BAL 
eosinophil count of >40 % and blood 
AEC of >1000 cells/μL are typical. 
Blood and alveoli eosinophils may be 
elevated to over 5000 cells/μL and 60 
%, respectively. Laboratory findings in 
addition to leukocytosis and peripheral 
Aristotle Biomedical Journal, Vol 2, No 1 e-ISSN: 2653-9748 
 
23 
 
eosinophilia include elevated serum 
IgE and markers of inflammation, such 
as erythrocyte sedimentation rate and 
C-reactive protein. (Philit F. et. al., 
2002; Shorr AF et. al., 2004)  In 
contrast to AEP, CEP does not 
progress to acute respiratory failure. 
Characteristic imaging findings in CEP 
include dense, multifocal 
consolidations in a bilateral and 
peripheral distribution on CXR. 
Findings on chest CT include bilateral 
consolidations and a ground-glass 
appearance. (Cottin V. et. al., 2005; 
Philit F. et. al., 2002) Treatment 
regimens include systemic 
corticosteroid therapy, which typically 
produces a favorable response and 
rapid improvement. The course may be 
relapsing and remitting in some 
patients, with up to 50 % of patients 
experiencing a relapse of symptoms 
one or more times after treatment. 
Management also involves good 
control of underlying asthma, and 
some patients may require long-term 
oral corticosteroid treatment to keep 
both asthma and CEP well controlled. 
(Stephanie S. et. al., 2016; Philit F. et. 
al., 2002) 
A previous study describes the 
occurrence of chronic eosinophilic 
pneumonia following RT after surgery 
for breast cancer in five female 
patients, with a mean age of 68 yrs 
(range 49–77) suggesting that radiation 
to the lung may promote the 
development of chronic eosinophilic 
pneumonia similar to that described for 
organising pneumonia. (Akuhota P. et. 
al., 2012; Cottin V.  et. al., 2012) All 
five patients had been treated by 
surgery for localized breast carcinoma. 
In all patients, breast surgery was 
followed by RT. Priming of alveolitis 
by radiation therapy to the breast might 
promote chronic eosinophilic 
pneumonia, which depends on genetic 
or acquired characteristics of patients 
and/or further stimulation that may 
trigger a T-helper cell type 2 form of 
lymphocyte response, especially in 
patients with asthma or other atopic 
manifestations. All patients had a 
history of asthma and/or allergy. A 
strong association between idiopathic 
chronic eosinophilic pneumonia and 
asthma is now well established. 
(Crestani B. et. al., 1998) At the onset 
of eosinophilic pneumonia, all patients 
were symptomatic. Chest radiograph 
showed pulmonary infiltrates, 
unilateral, which is a feature that is 
unusual in idiopathic chronic 
eosinophilic pneumonias, (Cottin V. et. 
al., 2004) further suggesting that RT 
may have contributed to the 
development of this syndrome, and 
limited to the irradiated lung in three 
patients, and bilateral in two. 
Pulmonary opacities were migratory in 
one patient. All patients had blood 
eosinophilia >1.0 * 10^9 L^-1 and/or 
eosinophilia >40% at bronchoalveolar 
lavage differential cell count. The 
median time interval between the end 
of radiation therapy and the onset of 
eosinophilic pneumonia was 3.5 
months (range 1–10).The time course 
of the chronic eosinophilic pneumonia 
was compatible with a role of RT, 
since previous studies have 
demonstrated that radiation- induced 
organising pneumonia may develop 
within a year after the completion of 
RT. (Akuhota P. et. al., 2012; 
Marchand E. et. al., 1998) All patients 
rapidly improved with oral 
corticosteroids without sequelae. 
Relapse occurred in two patients after 
treatment withdrawal. The eosinophilic 
pneumonia again completely resolved 
after corticosteroids were resumed. 
The authors hypothesize that chronic 
eosinophilic pneumonia may be 
facilitated by lung irradiation. Indeed, 
a slightly elevated number of 
eosinophils in bronchoalveolar lavage 
cell count have been reported in 
patients receiving RT following breast 
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cancer surgery. (Marchand E. et. al., 
2003) RT induces a diffuse bilateral 
and persistent lymphocytic alveolitis. 
(Bayle JY et. al., 1995) The 
development of chronic eosinophilic 
pneumonia may then be triggered by 
other factors such as drugs, Aspergillus 
infection, and environmental 
exposures. The authors speculate that 
antigenic stimulation may trigger a 
Th2-type of lymphocyte response 
when occurring in the weeks following 
lymphocyte priming by RT, thus 
leading to the occurrence of chronic 
eosinophilic pneumonia. The Th2- type 
immunological response may also be 
further facilitated by individual 
susceptibility and genetic factors, 
which were indeed suggested by a 
history of asthma or allergy in patients 
in that study. In conclusion, these 
observations suggest that chronic 
eosinophilic pneumonia may be 
included in the spectrum of potential 
pulmonary changes secondary to 
radiation therapy to the chest. 
Although a causal relationship between 
radiation therapy and chronic 
eosinophilic pneumonia cannot be 
definitively established from that 
descriptive study, the authors 
hypothesize that priming of alveolitis 
by radiation therapy to the breast may 
result in either chronic eosinophilic 
pneumonia or organising pneumonia, 
depending on the genetic or acquired 
characteristics of patients and/or 
further triggering factors. 
Our knowledge about the predictive 
factors of relapse of CEP is limited. 
One report has assessed the predictive 
factors of CEP relapse, and to date, it 
is not known which factors are 
predictive of relapse of CEP. (Bjemer 
L. et. al., 1990; Roberts CM. et. al., 
1993). The cessation of smoking stops 
the relapse of CEP and it is advised in 
CEP patients. Other factors on 
presentation, including age, sex, his- 
tory of dust exposure, underlying 
disorders (asthma and allergic 
disorders), respiratory failure, 
peripheral eosinophilia, serum IgE 
level (>1,000 IU/mL), rate of 
eosinophils in the BALF, CD4/8 ratio 
in the BALF ,and inhaled steroid 
therapy, were not significant predictive 
factors by univariate analysis. 
Although corticosteroid therapy 
remains a mainstay of CEP treatment, 
prolonged corticosteroid 
administration may induce metabolic 
and infectious complications.Future 
studies are needed to clarify the effects 
of prolonged corticosteroid therapy on 
the cardio- vascular system in CEP 
patients. One additional patient of the 
study developed pNTM, for which 
corticosteroid is a risk factor. The 
limited number of patients with pNTM 
did not allow us to assess whether the 
incidence of pNTM was higher in our 
CEP patients than that already 
reported. (Takashi Ishiguro et. al., 
2016) Additional treatment options are 
expected in the future. A history of 
smoking was a predictive factor for 
relapse of CEP at the time of initial 
diagnosis. One possible explanation of 
the results is the contribution of 
smoking to the development or 
maintenance of eosinophilic infiltration 
in the lung. (Oyama Y. et. al., 2015) 
Although no reports have suggested an 
association between smoking and CEP, 
there is significant overlap between 
CEP and acute EP, for which a strong 
association exists with cigarette 
smoking. (Bjermer L. et. al., 1990; 
Sakatani M. et. al., 2005) Smoking 
causes cellular and molecular changes 
that can lead to inflammation. In 
response to smoking, inflammatory 
signaling is altered by airway epithelial 
cells and macrophages, which, 
according to the signaling pathway 
used, results in an increase of 
lymphocytes, eosinophils, neutrophils, 
and mast cells in the lungs. In response 
to the exposure to smoking, a number 
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of proteins are upregulated and 
secreted, many of which have 
immunomodulatory activities that 
contribute to the pathogenesis of 
disease. (Bjermer L. et. al., 1990; 
Botelho FM. et. al., 2011) The 
inflammatory process induced by 
smoking is halted by its cessation, and 
all of our patients stopped smoking 
after the diagnosis of CEP, which may 
have helped to prevent the relapse of 
CEP. Large, prospective studies will be 
needed in the future to clarify this 
matter. CEP frequently relapses, and a 
history of smoking in patients at the 
time of the initial diagnosis of CEP 
was found to be a negative predictive 
factor for relapse of CEP. There may 
be some population of CEP patients in 
whom smoking contributes to the 
development or maintenance of CEP. 
The relapse of CEP may be halted by 
smoking cessation, which is strongly 
suggested in CEP patients.
 
In a group study, patients with CEP 
received oral prednisolone for either 3 
months (3-month group) or 6 months 
(6-month group), followed by 2 years 
observation. All patients were treated 
with an initial dose of prednisolone of 
0.5 mg/kg perday, which was then 
tapered and discontinued at either 3 or 
6 months. In the final analysis, there 
were 23 patients in the 3-month group 
and 21 patients in the 6-month group. 
All patients showed a good response to 
prednisolone treatment. There were 12 
(52.1%) relapses in the 3-month group 
and 13 (61.9%) relapses in the 6-month 
group. No significant difference was 
found in the cumulative rate of relapse. 
All relapse cases showed improvement 
upon resumption of prednisolone 
treatment. No difference was observed 
in the rate of relapse between the 3- 
and 6-month prednisolone treatment 
groups for patients with CEP. In the 
study the efficacy and safety of 3- and 
6-month prednisolone treatment for 
patients with CEP was 
compared.Collectively, these data 
demonstrate that the efficacy of 3 
months of prednisolone treatment may 
be equivalent to that of 6 months of 
treatment for patients with CEP, 
particularly in relation to relapse. 
Given the risks of long-term 
prednisolone treatment, 3 months of 
treatment may represent a more 
suitable and even feasible therapeutic 
option for patients with CEP (Akuhota 
P. et. al., 2012).  
Drug-induced EP is a rare condition. In 
total, only 228 cases were reported 
between 1990 and March of 2017. 
Ultimately, 196 full-text case reports 
met the criteria to be included in the 
following analysis. Many medications 
were implicated in drug-induced EP 
and the most commonly cited drugs 
were daptomycin, mesalamine, 
sulfasalazine, and minocycline. Almost 
every family of medication was found 
to be implicated. Moreover, A higher 
prevalence among a few 
pharmacological families such as 
antibiotics, (Nathan N. et. al., 2012; 
Crotty Alexander et. al., 2015) 
nonsteroidal anti-inflammatory drugs 
(Hirai J. et. al., 2017; Klerkx S. et. al., 
2009) and antiepileptic drugs was 
found, (Anan E. 
 
et. al., 2009) which 
suggests the possibility that there is a 
connection between the pathogenesis 
of EP and the mechanism of action of 
those commonly used medications. 
(Nathan N. et. al., 2012; Uchiyama H. 
et. al., 2008; Klerkx S. 
 
et. al., 2009). 
Regardless of age or sex, drug-induced 
EP should be suspected in any patient 
who has recently started taking a new 
medication and presents with new-
onset dyspnea, bilateral infiltrates on 
chest radiograph, and peripheral blood 
eosinophilia with a negative 
eosinophilia work-up. 
Given the fact that our patient was an 
infant, Eosinophilic pneumonias in 
children should be 
explored.Eosinophilic pneumonia is 
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not common in the pediatric 
population. The mean age is typically 
in the late 20s. (Sauvaget E. et. al., 
2010)
 
Only three pediatric cases of 
acute idiopathic EPs have been 
described in France in the last decade. 
(Kim JH. et. al., 2013) Despite their 
rarity, the etiological approach to EP 
has to be well-defined, as some causes 
can be rapidly life-threatening
 
(Rizos 
E. et. al., 2013) without initiation of 
the proper treatment. An extensive 
description of adult EPs has been 
proposed, (GiovanniniChami L. et. al., 
2014; Lodha R. et. al., 2013) but 
specific descriptions of childhood EPs 
in both developing and developed 
countries and their etiological 
approach have not been reviewed to 
date.  
The etiological approach has to be well 
documented in order to diagnose 
potentially life-threatening conditions. 
Asthma is a heterogeneous disease, 
which is characterized by chronic 
airway inflammation, episodic 
respiratory symptoms, and associated 
with variable expiratory airflow 
limitation, and can be divided into 
different clinical phenotypes. 
(Lambrecht BN et. al., 2015; Fa-Ping 
Wang et. al., 2018)
 
Based on the 
sputum and peripheral blood cellular 
profiles, asthma can be classified into 
eosinophilic or non-eosinophilic. (R. 
H. Green et. al., 2002; Imran Iftikhar 
et. al., 2018; McGrath KW. et. al., 
2012) Since eosinophilia can be seen 
across multiple clusters of asthma and 
disease severity, focus is shifting 
toward identifying different 
mechanisms that cause eosinophilia. 
(Pang PH. et. al., 2017; Jatakanon A. 
et. al., 2000). Among these are 
elevated interleukin (IL)-4 and IL-13 
expression in early-onset atopic asthma 
and predominant IL-5 expression in 
later-onset, or less-atopic 
asthma.Understanding the 
heterogeneity of the airway 
inflammation in severe asthma is of 
particular importance to predict future 
risk of exacerbations and response to 
therapy. Asthma exacerbations are 
associated with substantial morbidity 
and mortality. (Carr TF. et. al., 2018). 
Decreasing the asthma exacerbations 
rate is a key goal of asthma 
management. The presence of 
eosinophilic airway inflammation is 
associated with poorer asthma control 
and increased risk of exacerbations, 
and is a good predictor of a favorable 
response to corticosteroids. Quite a 
few outcomes in asthma have 
underlying refractory asthma, in whom 
standard therapies are ineffective. 
(Gibson PG, 2009) Several new 
‘biologics’ have emerged as promising 
personalized medicines specifically in 
the treatment of severe eosinophilic 
asthma. ‘Biologics’ are drugs such as 
omalizumab, Anti-interleukin-5 
monoclonal antibodies ( mepolizumab, 
reslizumab, benralizumab) and so on, 
which are produced by living cells 
through biological processes, and 
mimic natural biological substances 
such as antibodies targeting specific 
inflammatory pathways. The effects of 
the cytokines in the eosinophils are a 
matter of current research. Eosinophil 
recruitment and production is due to 
Th2 lymphocyte stimulation, with the 
help of cytokines including IL-3, IL-4, 
IL-5, IL-13 
[114]
. According to Stone et 
al., these interleukins function in 
different ways. IL-4 and IL-13 
stimulate immunoglobulin (Ig) E 
production and promote eosinophil 
recruitment by increasing expresssion 
of eotaxin (CCL11 and CCL26) and 
endothelial cell vascular cell adhesion 
molecule 1 (VCAM1). IL-5 mediates 
enhanced eosinophil production, 
eosinophil egress from the bone 
marrow, and eosinophil activation and 
survival. This cytokine is specific to 
eosinophil development but is not 
responsible for fostering eosinophil 
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infiltration of specific tissues. Most 
eosinophils that enter circulation from 
the bone marrow traffic to specific 
tissues and never return to circulate in 
the peripheral bloodstream. The 
process of eosinophils trafficking to 
tissues is thought to be overseen by T 
cells responding to antigen- presenting 
cells.However, when inflammation 
regulated by Th2 cells is present, 
eosinophils will home to other organs 
including the lungs and skin.Once 
trafficking to tissues is complete, the 
eosinophil attaches to extracellular 
matrix protein, fibronectin, which 
binds the eosinophil to specific tissues. 
Subsequently, the eosinophil receives a 
signal to degranulate and releases the 
preformed components of its granules, 
such as proteins as well as cytokines 
and chemokines. (Masoli M. et. al., 
2004; Chung KF. et. al., 2014)  In 
another study the authors speculate that 
IL-5 is essential for eosinophilic 
migration to the lung.  
Most diseases require corticosteroid 
therapy, both systemic and those 
targeted at specific tissues, with 
inconsistent results and cure rates. 
New therapies to target the 
inflammatory cascade remain at the 
forefront of research in eosinophilic 
disease processes.However, despite the 
use of high dosages of these drugs, 
even when associated with recurrent 
and long-lasting courses of systemic 
corticosteroids; some patients with 
refractory eosinophilic asthma do not 
achieve an adequatecontrol of their 
disease. Such subjects can thus 
significantly benefit from add-on 
biological therapies. 
The first monoclonal antibody for 
asthma was omalizumab, a humanized 
monoclonal antibody against IgE used 
since 2003 in adults, adolescents and 
children over 6 years of age with 
moderate to severe persistent allergic 
asthma inadequately controlled with 
standard therapy. It improved asthma 
symptoms and health-related quality of 
life. It also reduced exacerbations and 
daily inhaled corticosteroid dose. 
(Kumar R. et. al., 2014). Response to 
omalizumab was better in asthmatics 
with increased biomarkers of T2 
immunity and eosinophilic 
inflammation.  
Anti-interleukin-5 (IL-5) monoclonal 
antibodies are the second class of 
biological therapy for severe 
eosinophilic asthma. IL-5 cytokine 
plays an important role in the 
maturation and activation of 
eosinophils as mentioned before. 
Mepolizumab is a humanized mono- 
clonal antibody that binds to IL-5, 
preventing it from binding to IL-5 
receptors. The first large phase IIb/III 
trial (DREAM study) showed that 
mepolizumab at a range of doses 
significantly reduced severe 
exacerbation rate in subjects with 
recurrent exacerbations and evidence 
of eosinophilic inflammation. 
(Adkinson NF et. al., 2009) 
Mepolizumab has also been shown to 
have steroid- sparing effects by 
significantly reducing daily systemic 
corticosteroid use compared to 
placebo, while maintaining its 
exacerbation reduction effect. (Stone 
KD et. al., 2010) The efficacy of 
mepolizumab appeared to be more 
pronounced in subjects with higher 
baseline blood eosinophil levels and 
more frequent exacerbations, with no 
benefit in exacerbation reduction in 
those with a blood eosinophil count 
<150cells/L. On the strength of these 
positive trial results, it has since been 
licensed for use in severe eosinophilic 
asthma. According to another study, 
mepolizumab significantly reduces the 
risk of exacerbations requiring 
hospitalization or a visit to the 
emergency room. Last but not least, 
previous studies have shown that 
mepolizumab is associated with a 
clinically acceptable safety profile 
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across a number of conditions. 
(Normansell R. et. al., 2014; I.D. 
Pavord et. al., 2012; Bel E. H. et. al., 
2014; Steven W. Yancey et. al., 2017; 
Haldar P. et. al., 2009) Mepolizumab 
therefore represents an important 
treatment option for patients with 
severe eosinophilic asthma, and 
addresses a patient population that 
currently has a high unmet need and 
limited treatment options.
 
Reslizumab, 
another monoclonal antibody targeting 
IL-5, was also recently licensed for use 
in severe eosinophilic (≥400 blood 
eosinophils/L) asthma following phase 
III trials demonstrating significant 
improvement in forced expiratory 
volume in 1 second (FEV1), asthma 
control scores, asthma-related quality 
of life and frequency of asthma 
exacerbations. (Ortega H. G. et. al., 
2014) However, when used across a 
broad range of blood eosinophil 
counts, reslizumab had no effect on 
lung function and asthma control. 
(Flood-Page P. et. al., 2007). 
Benralizumab differs from 
mepolizumab and reslizumab as it acts 
on the alpha chain of the IL-5 receptor 
causing eosinophil apoptosis. Two 
recent phase III trials in subjects with 
inadequately controlled asthma, 
frequent exacerbations and elevated 
blood eosinophil count showed 
significant reduction of annual asthma 
exacerbation rate compared to placebo 
(Roufosse F. E. et. al., 2013; 
Straumann A. et. al., 2010).  
Inhibiting other T2-cytokines such as 
IL-13 neutralization (Lebrikizumab 
and Tralokinumab) or the alpha chain 
of the IL-4 receptor which attenuates 
both IL-4 and IL-13 signaling 
(Dupilumab) are attractive targets. 
None of these strategies have 
demonstrated an effect on reducing 
eosinophilic inflammation, but benefits 
for these approaches are greater in 
those with upregulated T2-immunity 
and eosinophilic inflammation. Recent 
phase III studies for Lebrikizumab 
failed to demonstrate consistent benefit 
for reduction in asthma exacerbations. 
Findings from a phase IIb study of 
Dupilumab were more encouraging, 
showing reductions in exacerbation 
frequency and improvements in 
symptoms in all comers with greatest 
response in those with eosinophilic 
inflammation. (M. Castro et. al., 2015; 
L. Bjermer et. al., 2016) 
In addition to biological therapy, small 
molecule inhibitors have shown 
promising results in severe asthma. 
Prostaglandin D2 (PGD2) is a 
prostanoid mainly produced by mast 
cells, which binds and activates G 
protein-coupled receptors.
 
 
Many studies have tried to compare the 
efficacy of Anti IL-4, IL-5 and IL-13 
Drugs for treatment of eosinophilic 
asthma. A network meta-analysis has 
shown that all treatments were 
comparable in terms of magnitude of 
improvement in FEV1 (except for 
tralokinumab) and AQLQ (except for 
tralokinumab and lebrikizumab). 
However, in the analysis of ACQ 
scores, mepolizumab had the greatest 
effect in terms of magnitude of 
improvement. Additionally, only 
dupilumab and reslizumab were 
associated with significantly less 
asthma exacerbations on treatment 
compared to others.In terms of 
comparison in this network meta-
analysis, mepolizumab as a drug is at a 
disadvantage, primarily because the 
drug was not included in the sub-group 
analyses. Even otherwise, controversy 
exists over the apparent superiority of 
the newer drugs (such as 
benralizumab) over mepolizumab. 
Perhaps future trials on mepolizumab 
could compare the drug with other 
drugs by classifying based on 
biomarkers (Corren J. et. al., 2016; 
Bleecker E. R. et. al., 2016). 
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Table 2: Comparing acute and chronic eosinophilic pneumonia
 AEP CEP 
Etiology Unknown, though 
associated with 
environmental exposures 
Unknown, though 
associated with 
environmental exposures 
Presentation Acute symptoms which 
progress rapidly 
Subacute, milder 
symptoms 
Sex Male predominance 2:1 Female predominance 2:1 
Risk Higher incidence in 
smokers 
Higher incidence in 
nonsmokers 
Labs Normal eosinophil count 
to mild/moderate 
peripheral eosinophilia 
Leukocytosis, peripheral 
eosinophilia (absolute 
eosinophil count >1000 
cells/μL) 
BAL >25 % eosinophils >40 % eosinophils 
Imaging Diffuse hazy infiltrates on 
chest imaging 
Bilateral, dense multifocal 
consolidation on chest 
imaging 
Course Rapid progression to 
acute respiratory failure 
Indolent course which 
may be relapsing and 
remitting, without 
respiratory failure 
Atopy Asthma does not 
predispose individual 
Asthma predisposes 
individual 
Management Systemic corticosteroids Systemic corticosteroids 
 
The advent of a range of antibodies 
targeting different mechanisms in 
asthma should enable progress toward 
the goal of personalized medicine, in 
which existing biomarkers aid 
clinicians in matching each biologic 
therapy to the patient population most 
likely to benefit from that treatment. 
Future directions for research should 
include discovery of new biomarkers, 
exploration of combination therapies 
that target multiple pathways, and 
recognition of the disease underlying 
pathologies in additional patient 
subpopulations that might benefit from  
novel treatments (N. A. Hanania et. al., 
2016; S. Wenzel et. al., 2016; J. Nixon 
et. al., 2017).  
 
Conclusion 
As mentioned above Eosinophilic 
Pneumonia (EP) is a really complex 
and serious disease and the current 
treatment methods are not adequate  
 
sufficient and effective enough. Thus, 
the armamentarium for the treatment of 
severe eosinophilic pneumonia (EP) 
needs to be expanded. Future research 
is needed to give further insight into 
which patients are most likely to have 
the greatest response to which 
treatment, and to better define both 
response and failure to respond to 
these new therapies. This might require 
head-to-head pragmatic real life trials 
of licensed therapies. In conclusion, I 
am certain that with its overarching 
reach and relevancy too many patient 
populations, eosinophilic pneumonia 
(EP) will remain an important topic for 
many years to come. 
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